This bioconjugate allows for the simultaneous targeting of different cell types by the three biotinylated JM173 peptides, which act as selective CXCR4 receptor antagonists to target the BC cells [17], and one biotinylated C3 enzyme targeting the osteoclasts in the bone niche. The gene discussed is C3; the disease is breast cancer.